{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:10:12Z","timestamp":1776161412934,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T00:00:00Z","timestamp":1474848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The comparative efficacy of adalimumab (<jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content>) and infliximab (<jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content>) in Crohn's disease, and the benefit of initial combotherapy with an immunomodulator, are debated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To assess the best anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> treatment regimens in Crohn's disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included 906 biologic\u2010na\u00efve Crohn's disease patients [median age, 31 years (24\u201341)] and performed a retrospective analysis of 1284 therapeutic exposures to <jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content> (<jats:italic>n<\/jats:italic> = 521) or <jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content> (<jats:italic>n<\/jats:italic> = 763) between 2006 and 2015. An immunomodulator was associated during the first 4\u20136 months (initial combotherapy) during 706 therapeutic exposures (55%). Median duration of anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> therapy was 39 months (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 17\u201367). Primary outcomes were 6\u2010month and 2\u2010year response rates and drug survival. Logistic regression with propensity scoring and Cox proportional hazard analysis determined variables associated with outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The response rates at 6 months and 2 years were 64% and 44% on <jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content> mono, 86% and 70% on <jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content> combo, 72% and 45% on <jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content> mono, and 84% and 68% on <jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content> combotherapy, respectively. Differences between <jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content> were not significant, whereas combotherapy was superior to monotherapy (<jats:italic>P<\/jats:italic> &lt; 0.001). Drug survival was longer with combotherapy vs. monotherapy [adjusted hazard ratio 2.17 (1.72\u20132.70)] and not significantly different between <jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content>. During subsequent anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> exposures, <jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content> combotherapy fared better than other groups regarding response rates, drug survival, disease activity, hospitalisations and abdominal surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this retrospective analysis of a large tertiary centre cohort of Crohn's disease patients, <jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content> had similar efficacy as first line treatment, while initial combotherapy with an immunomodulator improved all outcome measures.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.13808","type":"journal-article","created":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T10:27:37Z","timestamp":1474885657000},"page":"1102-1113","source":"Crossref","is-referenced-by-count":48,"title":["Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease"],"prefix":"10.1111","volume":"44","author":[{"given":"J.","family":"Cosnes","sequence":"first","affiliation":[{"name":"Department of Gastroenterology Saint Antoine Hospital APHP and Paris VI University Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Sokol","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Saint Antoine Hospital APHP and Paris VI University Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Bourrier","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Saint Antoine Hospital APHP and Paris VI University Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Nion\u2010Larmurier","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Saint Antoine Hospital APHP and Paris VI University Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Wisniewski","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Saint Antoine Hospital APHP and Paris VI University Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Landman","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Saint Antoine Hospital APHP and Paris VI University Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Marteau","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Saint Antoine Hospital APHP and Paris VI University Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Beaugerie","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Saint Antoine Hospital APHP and Paris VI University Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Perez","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Saint Antoine Hospital APHP and Paris VI University Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Seksik","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Saint Antoine Hospital APHP and Paris VI University Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,9,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct1209614"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.06.010"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.03.038"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw008"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12076"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw152"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0134-5"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.322"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.12.025"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.334"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365528909091339"},{"key":"e_1_2_7_13_1","first-page":"117","volume-title":"Advanced therapy in Inflammatory Bowel Disease Volume 1","author":"Cosnes J","year":"2011"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.30487.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.212712"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/269076"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301971"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.02.031"},{"key":"e_1_2_7_19_1","first-page":"A1","article-title":"SONIC: a randomized double\u2010blind controlled trial comparing Infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy","volume":"57","author":"Colombel JF","year":"2008","journal-title":"Gut"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.011"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13139"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.07.003"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00068-9"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000303"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.03.018"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.09.031"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.03.004"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13276"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13808","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13808","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.13808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T14:58:04Z","timestamp":1695481084000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.13808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,26]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/apt.13808"],"URL":"https:\/\/doi.org\/10.1111\/apt.13808","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,26]]}}}